Cheok Meyling H, Evans William E
St. Jude Children's Research Hospital, Department of Pharmaceutical Sciences, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA.
Nat Rev Cancer. 2006 Feb;6(2):117-29. doi: 10.1038/nrc1800.
The use of combination chemotherapy to cure acute lymphoblastic leukaemia (ALL) in children emerged in the 1980s as a paradigm for curing any disseminated cancer, and many of the therapeutic principles were subsequently applied to the treatment of other disseminated human cancers. Similarly, elucidation of the pharmacogenomics of ALL and its translation into new chemotherapeutic approaches might serve as a model for optimizing the treatment of other human cancers. Germline polymorphisms and gene-expression patterns in ALL cells have been linked to the toxicity and efficacy of chemotherapy for ALL and are beginning to emerge as useful clinical diagnostics.
20世纪80年代，联合化疗治愈儿童急性淋巴细胞白血病（ALL）成为治愈任何播散性癌症的范例，随后许多治疗原则被应用于其他播散性人类癌症的治疗。同样，对ALL药物基因组学的阐明及其转化为新的化疗方法可能成为优化其他人类癌症治疗的典范。ALL细胞中的种系多态性和基因表达模式与ALL化疗的毒性和疗效相关，并开始成为有用的临床诊断指标。
